PMC4036133_01
Chest CT images before (a) and after (b) erlotinib treatment, and before (c) and after (d) the addition of sorafenib. a Lesions of the right lung before the initiation of erlotinib treatment. b Partial remission of lower lobe lesions of the right lung 1 month after the initiation of erlotinib treatment. c Relapse of lower lobe lesions of the right lung with pachy shadows 4 months after the initiation of erlotinib. d Great mass in the lower lobe of the right lung with atelectasis, obstructive pneumonia and multiple patchy ground-glass opacities in the left lung 41 days after the addition of sorafenib.
cro-0007-0273-g01.jpg
PMC4036133_01_cro-0007-0273-g01.jpg
F1
Erlotinib (150 mg, once daily) was given to a 60-year-old non-smoking man who was diagnosed with stage IV lung adenocarcinoma with unknown status of EGFR mutation after failing to respond to the first-line chemotherapy with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 (every 3 weeks for 4 cycles) in September 2009 (fig. 1a). Partial remission was revealed by a chest computed tomography (CT) in October 2009 (fig. 1b) with limited grade II rash, and stable disease was confirmed by a follow-up chest CT until the progression of the disease shown in January 2010 with a PS score 1 (fig. 1c). A chest CT scan the 2nd day after his hospitalization revealed a great mass in the lower lobe of the right lung with atelectasis, obstructive pneumonia and multiple patchy ground-glass opacities in the left lung (fig. 1d).